Eli Lilly Rallies as Investors Revisit Obesity Pipeline and Bullish Price Targets

Eli Lilly and Company (LLY) is up 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed enthusiasm around Lilly’s obesity and diabetes franchise, helped by a stream of recent pipeline updates and at least one fresh higher price target from Wall Street. This could also reflect investors rotating back into large-cap drugmakers with visible growth drivers after Lilly’s recent pullback.

Details:

Lilly recently highlighted additional data for Foundayo, its oral GLP-1 medicine, including analyses tied to lower predicted long-term risks for type 2 diabetes and cardiovascular disease in adults with obesity or overweight.

The company also presented positive late-stage and mid-stage updates across its obesity portfolio, including new information on Zepbound and EloraTZP, reinforcing the breadth of its cardiometabolic pipeline.

Earlier this month, Lilly announced an expanded FDA approval for Jaypirca in certain previously untreated CLL/SLL patients, adding another positive regulatory development outside obesity.

A recent analyst note raised a price target on the stock, which likely added support as investors reassessed Lilly’s earnings power and pipeline optionality.

Sources:

Eli Lilly, SEC, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LLY Insider Trading Activity

$LLY insiders have traded $LLY stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:

PATRIK JONSSON (EVP & President, LLY Int'l) sold 6,500 shares for an estimated $7,638,149
ANAT HAKIM (EVP, GC & Secretary) sold 5,000 shares for an estimated $5,950,000
ILYA YUFFA (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares for an estimated $2,876,925
DONALD A ZAKROWSKI (SVP, Finance, & CAO) sold 2,000 shares for an estimated $2,370,020

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$LLY Hedge Fund Activity

We have seen 2,514 institutional investors add shares of $LLY stock to their portfolio, and 1,587 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 12,598,524 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,111,047,641
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 6,001,955 shares (+inf%) to their portfolio in Q2 2026, for an estimated $7,198,924,885
CAPITAL RESEARCH GLOBAL INVESTORS removed 3,759,507 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $4,509,265,481
WELLINGTON MANAGEMENT GROUP LLP removed 2,428,108 shares (-18.1%) from their portfolio in Q2 2026, for an estimated $2,912,345,578
FMR LLC added 2,121,444 shares (+8.1%) to their portfolio in Q2 2026, for an estimated $2,544,523,576
LILLY ENDOWMENT INC removed 1,520,000 shares (-1.7%) from their portfolio in Q2 2026, for an estimated $1,823,133,600
SG AMERICAS SECURITIES, LLC added 1,331,427 shares (+204.1%) to their portfolio in Q2 2026, for an estimated $1,596,953,486

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$LLY Congressional Stock Trading

Members of Congress have traded $LLY stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:

REPRESENTATIVE DAN NEWHOUSE sold up to $15,000 on 07/10.
REPRESENTATIVE MICHAEL A. RULLI sold up to $15,000 on 07/01.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $100,000 on 06/10.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$LLY Price Targets

Multiple analysts have issued price targets for $LLY recently. We have seen 11 analysts offer price targets for $LLY in the last 6 months, with a median target of $1350.0.

Here are some recent targets:

Trung Huynh from RBC Capital set a target price of $1500.0 on 07/08/2026
Robyn Karnauskas from Truist Securities set a target price of $1370.0 on 07/08/2026
Terence Flynn from Morgan Stanley set a target price of $1347.0 on 07/08/2026
Chris Schott from JP Morgan set a target price of $1400.0 on 07/07/2026
Carter Gould from Cantor Fitzgerald set a target price of $1350.0 on 07/06/2026
David Risinger from Leerink Partners set a target price of $1232.0 on 06/25/2026
Akash Tewari from Jefferies set a target price of $1350.0 on 06/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.